AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Peridontal and Intestinal Microbiota in Patients With Gingival Scarring Pemphigoid

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Universitaire de Nice
💬

In plain words

What the trial is, and whether it could suit you

Patients suffering from Mucous Membrane Pemphigoid with desquamative gingivitis (MMPg) generally present a more degraded periodontal condition compared with controls. Bullous disease could represent a risk factor for plaque-induced periodontal disease, and vice versa. Indeed, the dysbiotic periodontal microbiota could aggravate the gingival damage specific to MMP, either directly by activating inflammatory pathways, or indirectly by degrading cellular and matrix components. On the other hand, areas of erosive gingiva generated by the autoimmune process could increase the virulent power of periodontal pathobionts, by representing accessible, nutrient-rich connective surfaces. Moreover, in recent years, bacterial studies based on a high-throughput metagenomic approach have suggested the existence of a relationship between the oral and intestinal microbiota in patients with degraded period

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: Adults (over 18), non-smokers Arm 1 * MMPg (initial, persistent despite medical treatment, recurrent), periodontitis Arm 2 * non-MMPg, periodontitis, matched to cases on age, gender and severity of periodontitis Arm 3: \- non-MMPg, healthy periodontal conditions, matched to cases on age and gender Exclusion Criteria: * Antibiotic therapy and mechanical periodontal treatment within 3 months prior to study, other chronic general illness of immune or digestive origin
💊

What it tests

  • Plaque sampling and stool collection
  • periodontal examination
📍

Where

3 sites
Nice University Hospital
Nice, France
Paris hospital Pitié Salpetrière (APHP)
Paris, France
Paris hospital Bretonneau (APHP)
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy